ALEC
What one share of Alector holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biotechnology company developing therapies for neurodegenerative diseases, with a focus on areas of high unmet medical need. Our work is informed by advances in disease biology, including the roles of misfolded or deficient proteins, lysosomal dysfunction, and immune and neuronal pathway disruption.
Alector’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.13 |
|---|---|
| Profit | −$1.09 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.46 |
| Cash and investments | $1.55 |
| Debt | $0.09 |
| Book value | −$0.09 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $0.41 | −$3.55 | $0.09 | −$2.03 | — | −$5.69 |
| 2018 | $2.45 | −$4.62 | $0.17 | $11.11 | — | −$7.08 |
| 2019 | $0.34 | −$1.71 | $0.25 | −$1.86 | — | $2.82 |
| 2020 | $0.27 | −$2.45 | $0.06 | −$2.21 | — | $3.37 |
| 2021 | $2.58 | −$0.45 | $0.04 | $3.67 | — | $3.67 |
| 2022 | $1.62 | −$1.62 | $0.05 | −$0.30 | — | $2.59 |
| 2023 | $1.16 | −$1.56 | $0.03 | −$2.23 | — | $1.58 |
| 2024 | $1.04 | −$1.23 | $0.01 | −$2.39 | — | $1.28 |
| 2025 | $0.20 | −$1.39 | $0.00 | −$1.79 | — | $0.28 |